FB is a distraction . . .

From a stock perspective, the most important biotechnology meeting of the year is about to happen, the 2012 ASCO (American Society for Clinical Oncology) in Chicago starting June 1. This is the scientific gathering in which all of the most significant clinical trial results for new cancer therapeutics and diagnostics are presented in full for the first time, and the meeting is a major mover of share price for companies both large and small.

The next batch of clinical successes likely to win FDA approval that offer significant advances in patient care will be revealed, and new buying and selling opportunities will emerge.

Will you be posting your picks for this year again? They see to have worked out very well this past year.

It's good to cash in on cancer. Best of luck with that

Your comment is misguided.

Supporting small biotechnology companies attempting to develop novel and medically significant treatments and diagnostics for unmet medical needs helps those companies to raise the financing to conduct their work. Without the stock investors, there would be no venture capital investment in biotechnology start-ups, and the important products that emerge from the industry would never see the light of day.

I might be interested if it falls a bit below the IPO price, but I`m guessing that the underwriters will be supporting the $38 level with all their might for the next few weeks hours.

Fixed that for you. You can buy all the shares you want with a $36-handle in the pre-market right now.

EDIT: $34 now 15 minutes after the open.

EDIT: $33.10 now 22 minutes after the open.

Knight Capital head just blasted the NASDAQ on CNBC for the breakdown in FB trading on Friday.

The breakdown wouldn't have mattered if FB and the selling shareholders hadn't gotten so greedy and taken all the money off the table. You have to leave a little money on the table for buyers and also restrict liquidity to create a mania. Instead, the trading problems just exacerbated the lack of excitement.